Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Pfizer Inc. Add to portfolio

NYA:PFE, Oct 16, 08:36 UTC

Latest NYA:PFE News

Filter your feed

Apply Filter

Yesterday


News

Pfizer Inc. (PFE) Shares Bought by R.M.SINCERBEAUX Capital Management LLC – Fairfield Current

PFE

R.M.SINCERBEAUX Capital Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). 344,528 shares of the company’s stock were exchanged, compared to its average volume of 21,858,029. The stock has a market capitalization of $262.34 billion, a P/E ratio of 16.35, a P/E/G ratio of 2.23 and a beta of 0.96. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research note on Tuesday, July 3rd.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

+$96 Billion Opportunity for the Global Precision Medicine Market by 2023 - Featuring Abbott Labs, GE, GSK, Pfizer, J&J, Novartis, and more - ResearchAndMarkets.com

GE PFE +2 more GE PFE ABT GSK

+$96 Billion Opportunity for the Global Precision Medicine Market by 2023 - Featuring Abbott Labs, GE, GSK, Pfizer, J&J, Novartis, and more - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Global Precision Medicine Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering. The global precision medicine market is expected to have a significant compounded annual growth rate (CAGR) of 9.7% and have a market size in excess of USD 96 Bn by 2023. North America dominates the global market due to the high incidence of cancer and increasing government initiatives in the region. The global precision medicine market is classified into three primary segments - based on end use: pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies; based on therapeutics: cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases; and based on sub-market: big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics.

Read Full Details

Topics:
  • Business
  • Health
  • Science

Sunday, October 14


News

Alpha Cubed Investments LLC Has $708,000 Stake in Pfizer Inc. (NYSE:PFE) – Fairfield Current

PFE

Alpha Cubed Investments LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. Jensen Investment Management Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth approximately $110,291,000. 28,490,527 shares of the company’s stock were exchanged, compared to its average volume of 21,858,029. The stock has a market capitalization of $262.34 billion, a price-to-earnings ratio of 16.52, a price-to-earnings-growth ratio of 2.23 and a beta of 0.96.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Pfizer Inc. (PFE) Shares Sold by Colrain Capital LLC – Fairfield Current

PFE

Colrain Capital LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 15.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,675 shares of the biopharmaceutical company’s stock after selling 14,850 shares during the period. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $118,000. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a report on Tuesday, July 3rd.

Read Full Details

Topics:
  • Business
  • Financial
Social Chatter

Pfizer Inc. (NYA:PFE) social chatter is higher than usual

PFE
Trump says his successful pressuring of Pfizer happened "three weeks ago." It happened in July. He habitually moves up old good news so that it sounds more excitingly close to the presence.

Friday, October 12


News

Pfizer (PFE) PT Set at $48.00 by Independent Research – PressOracle

PFE

Goldman Sachs Group restated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research report on Tuesday, August 28th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the stock. The stock has a market cap of $262.34 billion, a PE ratio of 16.33, a PEG ratio of 2.23 and a beta of 0.96. In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of Pfizer stock in a transaction dated Monday, August 13th.

Read Full Details

Topics:
  • Business
  • Financial
  • Health
News

2018 World's Leading Generic Drug Companies: Mylan, Novartis, Pfizer, Sun Pharma & Teva - Capabilities, Goals and Strategies - ResearchAndMarkets.com

PFE MYL

2018 World's Leading Generic Drug Companies: Mylan, Novartis, Pfizer, Sun Pharma & Teva - Capabilities, Goals and Strategies - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "2018 World's Leading Generic Drug Companies: Capabilities, Goals and Strategies" report has been added to ResearchAndMarkets.com's offering. This report is part of the Competitive Analysis Series to help current suppliers and potential market entrants realistically assess their financial, technological and marketing capabilities in relation to the leading competitors. In the dynamic and fragmented Generic Drug industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.

Read Full Details

Topics:
  • Business
  • Financial
  • Science
News

Intercontinental Wealth Advisors LLC Sells 12,111 Shares of Pfizer Inc. (PFE) – Fairfield Current

PFE

Intercontinental Wealth Advisors LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 17.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The stock has a market capitalization of $262.34 billion, a price-to-earnings ratio of 16.22, a P/E/G ratio of 2.23 and a beta of 0.96. During the same quarter in the prior year, the company posted $0.67 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year. In other news, CEO Ian C. Read sold 486,753 shares of the stock in a transaction that occurred on Monday, July 16th.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Why Pfizer’s Share Price Fell in the Last Two Days

PFE

On October 10, Pfizer (PFE) closed at $44.51, which was 2.11% lower than its closing price the previous day. The stock suffered in the broader market sell-off on October 11 due to concerns about interest rate hikes by the Fed in the rest of 2018. On October 11, Pfizer closed 3.82% lower than the closing price the previous day.

Read Full Details

Topics:
  • Business
  • Financial
News

Pfizer settles New York probe into 'deceptive' copay coupons

PFE

NEW YORK (Reuters) - Pfizer Inc on Thursday settled charges by New York's attorney general that it misled consumers in its drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out. The drugmaker agreed to pay $500,000 in fines and costs, and make more than $200,000 in restitution over the coupons, which can help consumers burdened by health insurance plans that carry high copayments and deductibles. Pfizer's coupons said consumers would "PAY NO MORE THAN" $15, $20 or $25 for Estring to treat vaginal atrophy, Quillivant XR and Quillichew ER for attention deficit hyperactivity disorder, and Flector patches for acute pain from minor injuries. New York Attorney General Barbara Underwood said this was "deceptive" because Pfizer buried limits on the total savings in the small print, and that thousands of consumers ended up paying much more.

Read Full Details

Topics:
  • Business
  • Health
  • Financial